Aytu BioPharma, Inc. filings document a Nasdaq-listed pharmaceutical issuer with common stock trading under AYTU and a business centered on EXXUA, ADHD treatments, and other prescription products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor materials, and material agreements affecting the company's financing and capital structure.
The filing record also includes definitive proxy disclosures covering board matters, executive compensation, equity awards, and shareholder voting items. Other 8-K disclosures address loan and security agreement amendments with Aytu operating subsidiaries, warrant-related accounting and stockholder-approval language, and classification issues affecting reported liabilities or equity.
John A. Donofrio, Jr., a director of AYTU BioPharma, Inc. (AYTU), was granted 10,000 restricted shares on 10/03/2025. The grant carries a $0 per-share price and is described as restricted stock that vests on 10/03/2026.
Following the reported grant, the filing shows 13,762 shares beneficially owned by the reporting person. The Form 4 was signed on 10/07/2025 by an attorney-in-fact and includes a Power of Attorney exhibit.
Aytu BioPharma, Inc. filed a Form S-8 registration statement to register an additional 300,000 shares of common stock for issuance under its 2023 Equity Incentive Plan. These extra shares were authorized through a Plan Amendment that stockholders approved at the 2025 annual meeting on May 21, 2025. The amendment increases the total number of shares reserved for issuance under the 2023 Equity Incentive Plan to 500,000 shares, excluding any unissued or returned shares from prior plans. The filing relies on General Instruction E to Form S-8 and incorporates the company’s prior S-8 for this plan by reference.
Aytu BioPharma, Inc. filed a Form S-8 registration statement to register an additional 300,000 shares of common stock for issuance under its 2023 Equity Incentive Plan. These extra shares were authorized through a Plan Amendment that stockholders approved at the 2025 annual meeting on May 21, 2025. The amendment increases the total number of shares reserved for issuance under the 2023 Equity Incentive Plan to 500,000 shares, excluding any unissued or returned shares from prior plans. The filing relies on General Instruction E to Form S-8 and incorporates the company’s prior S-8 for this plan by reference.
Aytu BioPharma reported mixed 2025 results with strategic financing, asset impairments and a planned product launch. The company raised gross proceeds of $16.6 million in June 2025 through the sale of 2,806,688 common shares and 8,233,332 prefunded warrants; the prefunded warrants had an issuance fair value of approximately $12.3 million and $1.3 million of issuance costs were recorded in other (expense) income. In June 2025 the company recorded a $8.3 million impairment to product technology rights and also recognized a separate $2.7 million full impairment of other intangible assets. Aytu expects to launch EXXUA in the fourth calendar quarter of 2025 and capitalized commercialization rights with an estimated useful life through September 2030. Debt includes an amended Eclipse credit facility with $9.1 million outstanding on the revolving loan and an amended term loan (effective interest ~11.4%) after a $13.0 million increase; the company has a $100.0 million shelf registration with $100.0 million remaining available. The Consumer Health business was divested and is reported as discontinued operations.
Aytu BioPharma reported mixed 2025 results with strategic financing, asset impairments and a planned product launch. The company raised gross proceeds of $16.6 million in June 2025 through the sale of 2,806,688 common shares and 8,233,332 prefunded warrants; the prefunded warrants had an issuance fair value of approximately $12.3 million and $1.3 million of issuance costs were recorded in other (expense) income. In June 2025 the company recorded a $8.3 million impairment to product technology rights and also recognized a separate $2.7 million full impairment of other intangible assets. Aytu expects to launch EXXUA in the fourth calendar quarter of 2025 and capitalized commercialization rights with an estimated useful life through September 2030. Debt includes an amended Eclipse credit facility with $9.1 million outstanding on the revolving loan and an amended term loan (effective interest ~11.4%) after a $13.0 million increase; the company has a $100.0 million shelf registration with $100.0 million remaining available. The Consumer Health business was divested and is reported as discontinued operations.
Aytu BioPharma filed a Form 8-K reporting that on September 23, 2025 it issued a press release announcing its fiscal 2025 full year and fourth quarter operational and financial results and scheduled a conference call and live audio webcast for September 23, 2025 at 4:30 p.m. Eastern to discuss those results. The filing notes the press release is furnished as Exhibit 99.1 and explains that the exhibit is furnished, not filed, for Exchange Act purposes. The company states the call will be publicly accessible via webcast and telephone, with a replay available at the company’s discretion on its website and by telephone replay. No financial metrics, guidance, or other substantive disclosures are included in the 8-K text itself.
Aytu BioPharma filed a Form 8-K reporting that on September 23, 2025 it issued a press release announcing its fiscal 2025 full year and fourth quarter operational and financial results and scheduled a conference call and live audio webcast for September 23, 2025 at 4:30 p.m. Eastern to discuss those results. The filing notes the press release is furnished as Exhibit 99.1 and explains that the exhibit is furnished, not filed, for Exchange Act purposes. The company states the call will be publicly accessible via webcast and telephone, with a replay available at the company’s discretion on its website and by telephone replay. No financial metrics, guidance, or other substantive disclosures are included in the 8-K text itself.
AWM Investment Company, Inc. reports beneficial ownership of 619,874 shares of AYTU BioPharma common stock, equal to 6.9% of the class. These shares are held by Special Situations Private Equity Fund, L.P. (SSPE), for which AWM serves as investment adviser and over which AWM states it has sole voting and sole dispositive power.
The filing identifies David M. Greenhouse and Adam C. Stettner as controlling principals of AWM and members of MG Advisers, L.L.C., the general partner of SSPE. The filer certifies the securities were acquired in the ordinary course of business and are not held to change or influence control of the issuer.
Stonepine Capital and related reporting persons jointly report a 9.9% beneficial interest in AYTU BioPharma. The Schedule 13G discloses an aggregate position of 906,063 shares with shared voting and dispositive power and no sole voting or dispositive power. The reported position is calculated using 8,976,314 shares outstanding as of June 9, 2025.
The filing specifies the composition of the position as 812,676 shares of common stock plus prefunded and tranche warrants (prefunded warrants to acquire 2,446,883 shares; Tranche A and Tranche B warrants to acquire 815,217 shares each), and notes those warrants are subject to a 9.99% beneficial ownership limitation.
Kanen Wealth Management LLC, together with its affiliated funds Philotimo Fund LP and Philotimo Focused Growth & Income Fund, filed a Schedule 13G disclosing an aggregate ownership of 573,358 shares of AYTU BioPharma, Inc. ("AYTU") common stock as of 26 June 2025. This represents 6.4 % of AYTU’s 8,976,914 shares outstanding. Although the stake surpasses the 5 % reporting threshold, the 13G filing indicates the position is presently passive rather than activist in nature.
Stake distribution is as follows:
- Philotimo Fund LP: 384,150 shares (4.3 % of outstanding)
- Philotimo Focused Growth & Income Fund: 189,208 shares (2.1 % of outstanding)
- Kanen Wealth Management LLC / David L. Kanen: deemed beneficial owner of the full 573,358-share group position via control relationships.
The group expressly certifies the holdings were acquired without the intent to change or influence control of AYTU, satisfying the passive-investor criteria under Rule 13d-1. No additional transactions, purchase prices, or financing details were provided. While a 6.4 % passive stake signals meaningful external confidence, it does not by itself alter AYTU’s governance or capital structure.
Amendment No. 2 to Schedule 13G discloses that several related entities – Philotimo Fund LP, Philotimo Focused Growth & Income Fund (a series of World Funds Trust), Kanen Wealth Management LLC, and David L. Kanen – collectively own 166,268 shares of AYTU BioPharma, Inc. common stock.
Based on the issuer’s 6,170,246 shares outstanding as of 1 May 2025, the group’s holding represents approximately 2.7 % of the company’s equity.
Individually, Philotimo Fund holds 111,400 shares (1.8 %), while the Philotimo Focused Growth & Income Fund holds 54,868 shares (0.9 %). Kanen Wealth Management, as general partner and investment manager, and Mr. Kanen, as managing member, are each deemed to beneficially own all 166,268 shares through shared voting and dispositive power. No party reports sole voting or dispositive authority; all authority is shared among the reporting persons.
The filing is made pursuant to Rule 13d-1(c), indicating a passive investment below the 5 % threshold that would require a Schedule 13D. Each reporting person expressly disclaims beneficial ownership of shares not directly held. The event triggering the filing occurred on 22 May 2025, and the ownership percentages rely on share-count data from AYTU’s 14 May 2025 Form 10-Q.
Because the combined stake is below 5 %, the amendment does not signal a change in control or confer significant influence; however, it formally records the aggregated position and clarifies governance relationships among the entities.
Kanen Wealth Management LLC, its managing member David L. Kanen, and two affiliated funds (Philotimo Fund LP and Philotimo Focused Growth & Income Fund) filed an Amendment No. 1 to Schedule 13G reporting their collective ownership of 635,073 shares of AYTU BioPharma, Inc. (“AYTU”) common stock as of 15 May 2025.
The filing shows that the group now beneficially owns approximately 10.3 % of AYTU’s 6,170,246 outstanding shares (per AYTU’s 14 May 2025 Form 10-Q). Ownership is held passively under Rule 13d-1(c):
- Philotimo Fund LP: 425,500 shares (6.9 %)
- Philotimo Focused Growth & Income Fund: 209,573 shares (3.4 %)
- Kanen Wealth Management LLC & David L. Kanen: deemed beneficial owners of the full 635,073 shares (10.3 %) through control of the two funds
The signatories certify the securities were not acquired with the purpose of influencing control of the issuer. All voting and dispositive powers are reported as shared; none of the parties report sole power to vote or dispose of the shares. The principal business address for all reporting persons is 6810 Lyons Technology Circle, Suite 160, Coconut Creek, FL 33073.
The disclosure establishes Kanen Wealth Management and its affiliates as a newly recognized 10 % passive institutional holder of AYTU, a potentially supportive signal for other investors given the stake size and long-only filing status.